

ER β (H-150): sc-8974

BACKGROUND

Estrogen receptors (ER) are members of the steroid/thyroid hormone receptor superfamily of ligand-activated transcription factors. Estrogen receptors, including ER α and ER β , contain DNA binding and ligand binding domains and are critically involved in regulating the normal function of reproductive tissues. ER α and ER β have been shown to be differentially activated by various ligands. Receptor-ligand interactions trigger a cascade of events, including dissociation from heat shock proteins, receptor dimerization, phosphorylation and the association of the hormone activated receptor with specific regulatory elements in target genes. Evidence suggests that ER α and ER β may be regulated by distinct mechanisms even though they share many functional characteristics.

CHROMOSOMAL LOCATION

Genetic locus: ESR2 (human) mapping to 14q23.2; Esr2 (mouse) mapping to 12 C3.

SOURCE

ER β (H-150) is a rabbit polyclonal antibody raised against amino acids 1-150 of ER β of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Available as TransCruz reagent for Gel Supershift and ChIP applications, sc-8974 X, 200 μ g/0.1 ml.

APPLICATIONS

ER β (H-150) is recommended for detection of ER β of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for ER β siRNA (h): sc-35325, ER β siRNA (m): sc-35326, ER β siRNA (r): sc-77356, ER β shRNA Plasmid (h): sc-35325-SH, ER β shRNA Plasmid (m): sc-35326-SH, ER β shRNA Plasmid (r): sc-77356-SH, ER β shRNA (h) Lentiviral Particles: sc-35325-V, ER β shRNA (m) Lentiviral Particles: sc-35326-V and ER β shRNA (r)

ER β (H-150) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of ER β : 56 kDa.

Positive Controls: F9 cell lysate: sc-2245, NIH/3T3 whole cell lysate: sc-2210 or mouse thymus extract: sc-2406.


STORAGE

Store at 4 $^{\circ}$ C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



ER β (H-150): sc-8974. Western blot analysis of ER β expression in I-11.15 (A), F9 (B) and NIH/3T3 (C) whole cell lysates and mouse thymus (D) and mouse spleen (E) tissue extracts.

SELECT PRODUCT CITATIONS

- Garcia Pedrero, J., et al. 2002. Calmodulin is a selective modulator of estrogen receptors. *Mol. Endoc.* 16: 947-960.
- Yamashita, H., et al. 2003. Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induced apoptosis in T47D breast cancer cells. *Oncogene* 22: 1638-1652.
- Paez-Pereda, M., et al. 2003. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. *Proc. Natl. Acad. Sci. USA* 100: 1034-1039.
- Masuyama, H., et al. 2004. Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors. *J. Biol. Chem.* 279: 12020-12026.
- Paharkova-Vatchkova, V., et al. 2004. Estrogen preferentially promotes the differentiation of CD11c + CD11b (intermediate) dendritic cells from bone marrow precursors. *J. Immunol.* 172: 1426-1436.
- Yang, S.H., et al. 2004. Mitochondrial localization of estrogen receptor beta. *Proc. Natl. Acad. Sci. USA* 101: 4130-4135.
- Szabo, P.E., et al. 2004. Parent-of-origin-specific binding of nuclear hormone receptor complexes in the H19-Igf2 imprinting control region. *Mol. Cell. Biol.* 24: 4858-4868.
- Jiang, W.G., et al. 2005. Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER- β connection. *Biochem Biophys Res Commun.* 330: 253-262.
- Siewit, C.L., et al. 2010. Cadmium promotes breast cancer cell proliferation by potentiating the interaction between ER α and c-Jun. *Mol Endocrinol.* 24: 981-992.
- Barboro, P., et al. 2011. Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. *Prostate.* E-Published.